


# Developing a guidance resource for managing delirium in patients with COVID-19

David Meagher<sup>1\*</sup>, Dimitrios Adamis<sup>2</sup> , Suzanne Timmons<sup>3</sup>, Niamh A O'Regan<sup>4</sup>, Shaun O'Keeffe<sup>4</sup>, Sean Kennelly<sup>5</sup>, Catherine Corby<sup>6</sup>, Anna Maria Meaney<sup>7</sup>, Paul Reynolds<sup>7</sup>, Mas Mohamad<sup>8</sup>, Kevin Glynn<sup>1</sup> and Roisin O'Sullivan<sup>1</sup>

<sup>1</sup> Department of Psychiatry, University of Limerick School of Medicine, Limerick, Ireland

<sup>2</sup> Sligo-Leitrim Mental Health Services, Ballytovan Rd, Sligo, Ireland

<sup>3</sup> Geriatric Medicine, University College Cork, Centre for Gerontology and Rehabilitation, St. Finbarr's Hospital, Cork, Ireland

<sup>4</sup> Geriatric Medicine, Waterford University Hospital, Waterford, Ireland

<sup>5</sup> Geriatric and Stroke Medicine, Tallaght University Hospital Memory Assessment Service, Tallaght University Hospital, Dublin

<sup>6</sup> CL Psychiatry, University Hospital Limerick, Limerick, Ireland

<sup>7</sup> Psychiatry for Later Life, University Hospital Limerick, Limerick, Ireland

<sup>8</sup> Perinatal Psychiatry, University Hospital Limerick, Limerick, Ireland

As the COVID-19 pandemic escalates worldwide, it is apparent that many patients with more severe illness will also experience delirium. These patients pose a particular challenge in the application of optimal care due to issues with infectious risk, respiratory compromise and potential interactions between medications that can be used to manage delirium with antiviral and other treatments used for COVID-19. We describe a guidance resource adapted from existing guidelines for delirium management that has been tailored to the specific challenge of managing delirium in patients with COVID-19 infection. Issues around the assessment and treatment of these patients are examined and distilled into a simple (one-paged guidance resource that can assist clinicians in managing suspected delirium.

Received 20 April 2020; Revised 15 May 2020; Accepted 26 May 2020

**Keywords:** COVID-19, delirium, guidance.

## Background

The healthcare community is currently in the grip of a pandemic due to COVID-19 (coronavirus SARS-CoV-2) (Zhou *et al.*, 2020), with growing worldwide mortality especially amongst elderly and those with pre-existing comorbidities, such as cardiorespiratory disease, diabetes and dementia. In addition to fever and respiratory symptoms, a substantial number of patients experience neurological difficulties, with reports of 'impaired consciousness' in 15% of those with severe illness in one series (Mao *et al.*, 2020) and 'confusion' reported in 9% at presentation in another (Chen *et al.*, 2020; Meo *et al.*, 2020).

Against this backdrop, it can be expected that delirium will complicate illness course in many patients with COVID-19. Moreover, the management of delirium in these patients is especially challenging as the application of many non-pharmacological strategies to manage delirium is curtailed by the need to minimise infectious risk (LaHue *et al.*, 2020), while medications used in delirium management have recognised capacity

to cause respiratory depression and have interactions with antiviral and other agents used to treat COVID-19.

As a result, existing guidelines on delirium management need to be carefully considered and adapted to the needs of patients with COVID-19. From an Irish perspective, clinicians from the Department of Psychiatry at University Hospital Limerick have with psychiatry and geriatric medicine clinicians that have particular interest in the management of delirium to develop a user-friendly and practical guidance document that is tailored to the particular challenge of suspected delirium in patients with COVID-19. In this paper, we describe the development of this resource and examine emerging literature that addresses key considerations relevant to the provision of optimal care to patients with COVID-19 who experience delirium.

## Existing resources

The management of delirium in everyday clinical practice is typically guided by a variety of existing resources that include formal guidelines (e.g. National Institute for Health and Clinical Excellence, 2010; Scottish Intercollegiate Guidelines Network, 2019), as well as various guidance material developed by local

\*Address for correspondence: Professor David Meagher, Clinical Education and Research Centre, University Hospital Limerick, Dooradoyle, Limerick (Email: [david.meagher@ul.ie](mailto:david.meagher@ul.ie))

departments (e.g. Policy for management of suspected delirium Psychiatry for later Life service, University Hospital Limerick) as well as by National groups (e.g. Health Services Executive: early identification and management of delirium in the emergency department and acute medical assessment unit). These resources address many important aspects of delirium as it relates to the legion of possible causes that occur in everyday clinical practice including detection and diagnosis, investigation for underlying causes, non-pharmacological management and advice regarding the circumstances under which pharmacological interventions can be applied, including choice of agent, dosing and monitoring of response and adverse effects.

### Additional guidance resources

In response to the COVID-19 pandemic, a variety of position statements and guidance resources documents have emerged to supplement these existing resources by addressing the specific challenges posed by patients with COVID-19 in terms of minimising infectious risk through efficient recognition of delirium, prudent application of environmental and other non-pharmacological efforts to minimise the occurrence and impact of delirium in COVID-19 patients, and the key considerations around use of pharmacological interventions, including their rationale, interactions with other medications that may be used in these patients and potential for adverse effects (British Geriatrics Society, European Delirium Association, Old Age Psychiatry Faculty of the Royal College of Psychiatrists, 2020; Gee and Taylor, 2020; Liverpool Drug Interactions Group).

### Detection

A number of issues particular to delirium assessment in patients with COVID-19 are evident. Firstly, delirium detection must be sensitive to the need for rapid and efficient assessment that minimises the duration of interactions that can be physically and mentally demanding on highly morbid patients. The 4AT is a practical and simple tool for the efficient assessment of possible delirium that is brief (requires less than 2 minutes), has excellent patient coverage (i.e. allows assessment of patients with severe drowsiness or agitation who are less able to communicate) and does not require any special training. It is supported by at least 11 validation studies (involving >2500 patients) that indicate high sensitivity (83–100%) with moderate to high specificity (70–99%) for delirium ([seewww.4AT.com](http://www.4AT.com)) (Shenkin *et al.*, 2019). For these reasons, the 4AT has become the preferred tool that is recommended for delirium detection by recent guidelines and is suited to the challenges of COVID-19 as it is brief, minimally

demanding upon patients and does not include any elements (e.g. pen and paper) that require physical contact. It is important to note that where a patient is unable to engage with testing (e.g. the months backwards test), this is considered a failed performance and scored accordingly. This reduces the likelihood of patients with severe delirium being missed.

### Non-pharmacological management

Early reports from the Italian experience of the COVID-19 pandemic (di Giacomo *et al.*, 2020) have highlighted how providing a delirium-friendly care environment is extremely challenging for many patients with COVID-19 as for many the experience of being nursed in isolation by staff using Personal Protective Equipment (PPE) may create an anxiogenic and threatening care environment. In addition, many of the principles of routine management of the care environment may not be realistic, such as consistency of staffing, facilitated mobilisation, providing bedside sitters and involving family in care provision. However, many of the other elements to good care of those at risk of delirium continue to apply, such as optimising sensory abilities, clear and concise communication and careful attention to medication regimes to minimise use of deliriogenic medications and polypharmacy. In addition, in many centres, staff have identified creative ways of reducing the impersonal nature of providing care when using PPE, such as wearing large named identification photographs when engaging with patients receiving care in isolation.

Outbreaks of COVID-19 have become common in residential care settings in Ireland, as elsewhere, and in many cases delirium can be the principal presenting feature. Many such residents are frail, and some are approaching the end of life. It is usually appropriate to manage such residents in the nursing home, often with palliative care measures, unless it is judged that transfer an acute hospital may provide clinical benefit. This presents a challenging risk-benefit analysis that requires careful consideration of baseline functioning and the likely benefits of more intense supportive intervention versus the recognised risk of provoking or exacerbating delirium already delirium-prone persons. The detection and management strategies outlined in this paper can also be applied in nursing home settings, with adaptation according to the resources that are available in each setting.

### Assessing causation

Delirium can be secondary to insults located within the Central Nervous System (CNS) but also commonly occurs in response to disturbances that are primarily

## Management Tips for Suspected Delirium in patients with COVID-19

Delirium involves an acute disturbance of brain function that presents with cognitive impairment ('confusion') and behavioural disturbance that can significantly impact upon the ability to receive care. Delirium is expected to be common and pose a particular challenge in patients with COVID-19. The best treatment for delirium is to treat the underlying cause.

<h3>1. 4AT Rapid Clinical Test for Delirium</h3> <p><b>1. Alertness</b></p> <table border="0" style="width: 100%;"> <tr><td>Normal (fully alert, not agitated)</td><td style="text-align: right;">0</td></tr> <tr><td>Mild sleepiness (for &lt;10 secs after waking but then normal)</td><td style="text-align: right;">0</td></tr> <tr><td>Clearly abnormal</td><td style="text-align: right;">4</td></tr> </table> <p><b>2. AMT4</b> (Age, DOB, name of hospital, current year)</p> <table border="0" style="width: 100%;"> <tr><td>No mistakes</td><td style="text-align: right;">0</td></tr> <tr><td>1 mistake</td><td style="text-align: right;">1</td></tr> <tr><td>≥ 2 mistakes/ untestable</td><td style="text-align: right;">2</td></tr> </table> <p><b>3. Attention</b> (Months of year backwards)</p> <table border="0" style="width: 100%;"> <tr><td>Achieves ≥7 months correctly</td><td style="text-align: right;">0</td></tr> <tr><td>Starts but scores &lt; 7 months</td><td style="text-align: right;">1</td></tr> <tr><td>Untestable (too unwell / drowsy / inattentive)</td><td style="text-align: right;">2</td></tr> </table> <p><b>4. Acute change or Fluctuating symptoms</b></p> <table border="0" style="width: 100%;"> <tr><td>No</td><td style="text-align: right;">0</td></tr> <tr><td>Yes</td><td style="text-align: right;">4</td></tr> </table> <p><b>Total Score</b> —</p> <p style="background-color: #e0ffe0; padding: 5px;"> <b>≥ 4 : Probable delirium +/- cognitive impairment</b>  <b>1-3 : Possible cognitive impairment</b>  <b>0 : Delirium unlikely</b> </p> <p><b>2. Assess Potential Causes of Delirium: 'PINCH ME'</b></p> <p><b>P</b> – Is the person in pain? Has urinary retention been excluded?</p> <p><b>IN</b> – Infection: is there a possible infection?</p> <p><b>C</b> – Constipation: When was the last bowel movement?</p> <p><b>H</b> – Hydration/nutrition: Consider electrolyte imbalance, hypoxia, hypotension, hypoglycaemia?</p> <p><b>M</b> – Medication: omission of regular medication or addition of new medication</p> <p><b>E</b> – Environment: change of environment, noise or activity levels impacting sleep/ rest</p>	Normal (fully alert, not agitated)	0	Mild sleepiness (for <10 secs after waking but then normal)	0	Clearly abnormal	4	No mistakes	0	1 mistake	1	≥ 2 mistakes/ untestable	2	Achieves ≥7 months correctly	0	Starts but scores < 7 months	1	Untestable (too unwell / drowsy / inattentive)	2	No	0	Yes	4	<h3>3. Non-pharmacological strategies</h3> <p>In the COVID-19 outbreak, many of the usual strategies for delirium management may not be feasible, but three key things can still be done:</p> <ul style="list-style-type: none"> <li>• <b>3 R's:</b> verbally Reassure (loud, clear, slow voice), Reorientate, and Repeat (retention of information can be poor in delirium)</li> <li>• <b>Ensure</b> (working) hearing aids / clean glasses are available</li> <li>• <b>Medication review</b> for any omitted medications, or new medications (balancing need for opioids for dyspnoea with potential to worsen delirium)</li> </ul> <h3>4. Consider Pharmacological intervention for delirium if the patient or others are at immediate risk and/or urgent care is compromised</h3> <p>For a patient with COVID-19:</p> <ul style="list-style-type: none"> <li>• The preferred First line oral antipsychotic is <b>Olanzapine</b> as it appears to interact minimally with other COVID-19 medications - give 2.5mg orally, up to 10mg per day (see <a href="http://www.covid19-druginteractions.org">www.covid19-druginteractions.org</a>)</li> <li>• If intramuscular medication is required, <b>Haloperidol</b> 0.5mg-1mg may be <u>considered</u> (maximum of 4mg in 24 hours), if an ECG out rules QT prolongation/other arrhythmias and noting the risk of potential myocarditis in COVID-19.</li> <li>• <b>Benzodiazepines</b> are more likely than antipsychotics to cause respiratory depression and are associated with prolongation and worsening of delirium symptoms. Use should be limited to where antipsychotics are not tolerated or contra-indicated (e.g. Lewy Body dementia or Parkinson's disease) Where used, Flumazenil should be available for reversal.</li> </ul> <p>More detailed guidance is available at Early Identification and Management of Delirium in the Emergency Department/ Acute Medical Assessment Unit. <a href="https://dementiapathways.ie/care-pathways/acute-hospital-care">https://dementiapathways.ie/care-pathways/acute-hospital-care</a></p>
Normal (fully alert, not agitated)	0																						
Mild sleepiness (for <10 secs after waking but then normal)	0																						
Clearly abnormal	4																						
No mistakes	0																						
1 mistake	1																						
≥ 2 mistakes/ untestable	2																						
Achieves ≥7 months correctly	0																						
Starts but scores < 7 months	1																						
Untestable (too unwell / drowsy / inattentive)	2																						
No	0																						
Yes	4																						

Figure 1. Management tips for suspected delirium in patients with COVID-19.

located systemically, such as peripheral infection, organ failure or metabolic disruptions. The precise mechanisms by which COVID-19 may cause neurological manifestations are still unclear but may include direct CNS infection, access due to reduced blood-brain barrier integrity, retrograde neuronal transport, hypoxic damage, vascular mechanisms and neuroinflammatory responses, along with the many other causes that have been associated with increased delirium propensity. In addition, patients in isolation, requiring mechanical ventilation, with reduced sensory

input and mobilisation are all more prone to developing delirium (Kotfis *et al.*, 2020).

In addressing delirium, it is always important to recognise that it is a multifactorial condition, typically with more than one causative factor and that a variety of factors can serve as precipitating and/or aggravating issues. The primary aim of delirium treatment is to address the aetiological cause(s). The PINCH-ME algorithm (see Fig. 1) is frequently used to guide aetiological assessment and is applicable to patients with COVID-19.

**Table 1.** Drug interactions between commonly used medications in delirium and COVID-19 agents (adapted from Liverpool drug interactions group)

	ATZ	LPRT	REM	FAV	CHL	NIT	RIB	TOC
Haloperidol	↑♥	↑♥	↔	↔	↔♥	↔	↔	↔
Olanzapine	↔	↓	↔	↔	↔	↔	↔	↔
Risperidone	↑♥	↑♥	↔	↔	↑♥	↔	↔	↔
Quetiapine	↑♥	↑♥	↔	↔	↔♥	↔	↔	↔
Diazepam	↑	↑	↔	↔	↔	↔	↔	↔
Lorazepam	↔	↔	↔	↔	↔	↔	↔	↔
Midazolam	↑	↑	↔	↔	↔	↔	↔	↔

ATZ, atazanavir; LPRT, lopinavir/ritonavir; REM, remdesivir; FAV, favipiravir; CHL, chloroquine/hydroxychloroquine; NIT, nitazone; RIB, ribavirin; TOC, tocilizumab.

↑ indicates potential for increased medication effects and ↓ indicates potential for decreased medication effects. ♥ indicates potential cardiac toxicity that may cause QT and/or PR prolongation.

### Management of agitated and distressed patients with delirium

In addition, the delirious state can be highly problematic in terms of patient distress and behavioural disturbance. The use of antipsychotic agents in the management of delirium is the source of ongoing debate with the current consensus that these agents are not a treatment for delirium *per se* (Burry *et al.*, 2018; Nikooie *et al.*, 2019) but can be used to manage symptoms of delirium where the balance of risk in terms of potential adverse effects allows (Meagher *et al.*, 2018). Although the demographic pattern of older patients being prone to experiencing more severe illness with COVID-19 suggests that hypoactive presentations will be prominent (Meagher, 2009), a substantial minority will experience hyperactivity that impacts upon patient wellbeing in terms of distressing psychotic and affective disturbances, risk of falls and other injuries, ability to receive optimal care and elevated infectious risk. It may be expected that with reduced capacity to provide non-pharmacological supports, medications will need to be considered in a substantial percentage of these patients. However, these decisions are further complicated by heightened vulnerability to adverse effects from pharmacological treatments. In addition to the usual concerns about toxicity in terms of extrapyramidal effects, cardiotoxicity and cerebrovascular effects, patients with COVID-19 can be expected to be more vulnerable to respiratory depression and cardiac effects.

### Benzodiazepines

Although there is no evidence to support the use of benzodiazepines in the treatment of delirium among hospitalised patients except in alcohol or benzodiazepine withdrawal (Lonergan *et al.*, 2009) or in palliative care

(Finucane *et al.* 2020), they are still in use despite their documented capacity to cause or worsen delirium. Both antipsychotic agents and benzodiazepines have potential to cause respiratory depression, but this is particularly significant with benzodiazepines which are associated with dose-related centrally mediated respiratory depression (Ekstrom *et al.*, 2014; Vozoris, 2014) and, as such, benzodiazepines should only be used with great caution in patients with respiratory compromise (Shah *et al.*, 2017). In summary, benzodiazepine use should be avoided for treating delirium in COVID-19 infected patients (LaHue *et al.*, 2020) or should be limited to patients who cannot tolerate antipsychotics or who have other contraindications to their use (e.g. Parkinson's disease or Lewy body dementia) or have withdrawal or seizure-related symptoms. Where benzodiazepines are used, this should include careful monitoring of effects and an awareness that their respiratory effects can be reversed with flumazenil. It must equally be highlighted that benzodiazepines are perfectly appropriate as a palliative treatment for severe respiratory distress, including end-of-life care, and indeed have an important role here in palliation and reducing anxiety. This indication is clearly differentiated from their use specifically to treat delirium and/or worsened responsive behaviours.

### Antipsychotic agents

As such, where pharmacological treatment is required to counter the challenge of distressing psychosis and/or otherwise unmanageable behavioural disturbance, antipsychotic agents are considered the first choice intervention. Existing guidelines varying in suggested agents of first choice, with haloperidol, olanzapine, risperidone and quetiapine recommended as possible treatments. However, in the context of COVID-19,

cardiac effects, particularly when used in combination with antiviral agents, are an important concern and evidence suggests that olanzapine has a favourable profile compared to risperidone and quetiapine (see below), while haloperidol remains a useful option due to the range of routes by which it can be administered (see Table 1).

Where antipsychotic agents are used, it is important to monitor cardiac function and in particular to rule out QT prolongation with a baseline Electrocardiogram (ECG). Moreover, use of antipsychotics brings with it a risk of a variety of other potential adverse effects, with a significantly increased risk of cerebrovascular incidents especially in patients with pre-existing cognitive issues, such as dementia (Rao *et al.*, 2016), as well as extrapyramidal and anticholinergic effects (e.g. cardiac conduction effects and increased hyperpyrexia risk), with the latter more commonly attributed to olanzapine than other second generation antipsychotics (Gardner *et al.*, 2005). Of note, the evidence suggests that extrapyramidal effects are uncommon with low dose use (Burry *et al.*, 2018). Other evidence suggests that cardiac effects are rare where cumulative daily doses of intravenous haloperidol are lower than 2 mg, unless patients have additional risk factors for QTc prolongation (Meyer-Masseti *et al.*, 2010). Suggested doses are shown in Figure 1 with the usual rule of 'start low and go slow' particularly important given the age profile and level of morbidity of many patients with symptomatic COVID-19. In addition, patients experiencing hyperinflammatory states can have increased brain permeability to neurotoxins that in turn can confer greater sensitivity to adverse effects from psychotropic agents (Wu *et al.*, 2020).

### Potential interactions between psychotropic and antiviral agents

A further consideration relates to potential interactions between psychotropic agents and other treatments used in these patients, with antiviral agents a particular focus of concern. The Liverpool Drug Interaction Group (based at the University of Liverpool, UK), in collaboration with the University Hospital of Basel (Switzerland) and Radboud UMC (Netherlands), has collated information regarding interactions between over 400 medications (including psychotropics) and experimental COVID-19 therapies (e.g. atazanavir, lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, ribavirin, tocilizumab, interferon beta) (see [www.covid19-druginteractions.org](http://www.covid19-druginteractions.org)). This information indicates a favourable profile for olanzapine in terms of interactions with antiviral agents, while haloperidol, risperidone and quetiapine increase the exposure to potential adverse effects of many antiviral agents and

haloperidol warrants particular caution in respect of potential for effects on cardiac conduction.

### A guidance resource for managing delirium in COVID-19 patients

Taking all of these considerations into account, we have composed a guidance sheet that can assist non-expert clinicians in how to manage COVID-19 patients that have suspected delirium. It is brief (occupying one side of a page) and practical, addressing four steps in decision-making: (1) assessment for delirium using the 4AT, (2) assessing potential aetiological factors using the PINCH-ME algorithm, (3) guidance on non-pharmacological management and finally, (4) guidance on use of pharmacological interventions. While in many cases, clinicians will be comfortable in detecting and managing delirium, this guidance can assist where a more structured approach is needed. It can also serve as a useful support to guide efforts to assess and manage delirium in consultation with psychiatry services. This guidance provides a rapid response to the need to focus our efforts to manage delirium during the pandemic that has been disseminated to support everyday practice in local services and beyond. It can also provide a document that can be further developed in a more systematic way (e.g. consensus guidelines) over time as further evidence (e.g. around existing or additional treatments for COVID-19) emerges.

### Financial support

This article received no specific grant from any funding agency, commercial or not-for-profit sectors.

### Conflict of interest

The authors have no conflict of interest to disclose.

### Ethical standards

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committee on human experimentation with the Helsinki Declaration of 1975, as revised in 2008. The authors assert that ethical approval was not required for publication of this manuscript. All authors contributed to the development and writing of this article, including the guidance as well as the text of the article.

### References

British Geriatrics Society, European Delirium Association and Old Age Psychiatry Faculty of the Royal College of Psychiatrists (2020). Coronavirus: Managing delirium in confirmed and suspected cases. Published 19th March

- 2020 ([www.bgs.org.uk/resources/coronavirus-managing-delirium-in-confirmed-and-suspected-cases](http://www.bgs.org.uk/resources/coronavirus-managing-delirium-in-confirmed-and-suspected-cases)). Accessed April 18th 2020.
- Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, Fergusson DA, Bell C, Rose L** (2018). Antipsychotics for treatment of delirium in hospitalised non-ICU patients. *Cochrane Database of Systematic Reviews* 6, CD005594. doi: [10.1002/14651858.CD005594.pub3](https://doi.org/10.1002/14651858.CD005594.pub3)
- Chen N, Zhou M, Dong X, Qu J, et al.** (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 395(10223), 507–513. doi: [10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)
- di Giacomo E, Bellelli G, Peschi G, Scarpetta S, Colmegna F, de Girolamo G, Clerici M** (2020). Management of older people during the Covid-19 outbreak: recommendations from an Italian experience. *International Journal of Geriatric Psychiatry* doi: [10.1002/gps.5318](https://doi.org/10.1002/gps.5318).
- Ekström MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC** (2014). Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. *BMJ* 348, g445. doi: [10.1136/bmj.g445](https://doi.org/10.1136/bmj.g445)
- Finucane AM, Jones L, Leurent B, Sampson EL, Stone P, Tookman A, Candy B** (2020). Drug therapy for delirium in terminally ill adults. *Cochrane Database of Systematic Reviews* 1, CD004770. doi: [10.1002/14651858.CD004770.pub3](https://doi.org/10.1002/14651858.CD004770.pub3)
- Gardner DM, Baldessarini RJ, Waraich P** (2005). Modern antipsychotic drugs: a critical overview. *CMAJ* 172(13), 1703–1711. doi: [10.1503/cmaj.1041064](https://doi.org/10.1503/cmaj.1041064)
- Gee S, Taylor D** (2020). Covid-19 and pharmacological management of delirium. South London and Maudsley NHS Foundation Trust. 27th March 2020 (<https://www.dropbox.com/s/cl6q21e71fa7kk3/COVID%2019%20Delirium%2027%20March%20Final.pdf?dl=0>). Accessed April 18th 2020.
- Health Services Executive Dementia Pathways** (2020). Early Identification and Management of Delirium in the Emergency Department/Acute Medical Assessment Unit. Available at: <https://dementiopathways.ie/care-pathways/acute-hospital-care>.
- Kotfis K, Williams Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW** (2020). COVID-19: ICU delirium management during SARS-CoV-2 pandemic. *Critical Care* 24(1), 176. doi: [10.1186/s13054-020-02882-x](https://doi.org/10.1186/s13054-020-02882-x).
- LaHue SC, James TC, Newman JC, Esmaili AM, et al.** Collaborative Delirium Prevention in the Age of COVID-19. *Journal of the American Geriatrics Society* 2020. doi: [10.1111/jgs.16480](https://doi.org/10.1111/jgs.16480).
- Liverpool Drug Interactions Group** (2020). Interactions with experimental Covid-19 therapies: Antipsychotics/neuroleptics (<https://www.covid19-druginteractions.org/>). Accessed April 18th 2020.
- London** (2020). *National Institute for Health and Clinical Excellence* ([www.nice.org.uk/nicemedia/live/13060/49908/49908.pdf](http://www.nice.org.uk/nicemedia/live/13060/49908/49908.pdf)). Accessed April 17th 2020.
- Loneragan E, Luxenberg J, Sastre AA** (2009). Benzodiazepines for delirium. *Cochrane Database of Systematic Reviews* (4). doi: [10.1002/14651858.CD006379.pub3](https://doi.org/10.1002/14651858.CD006379.pub3)
- Mao L, Jin H, Wang M, et al.** (2020). Neurologic manifestations of hospitalized patients with Coronavirus disease 2019 in Wuhan, China. *JAMA Neurology*. doi: [10.1001/jamaneurol.2020.1127](https://doi.org/10.1001/jamaneurol.2020.1127).
- Meagher D** (2009). Motor subtypes of delirium: past, present and future. *International Review of Psychiatry* 21(1), 59–73. doi: [10.1080/09540260802675460](https://doi.org/10.1080/09540260802675460).
- Meagher D, Agar MR, Teodorczuk A** (2018). Debate article: antipsychotic medications are clinically useful for the treatment of delirium. *International Review of Psychiatry* 33, 1420–1427. doi: [10.1002/gps.4759](https://doi.org/10.1002/gps.4759).
- Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, et al.** (2020). Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. *European Review for Medical and Pharmacological Sciences* 24, 2012–2019.
- Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ** (2010). The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? *Journal of Hospital Medicine* 5, E8–E16. doi: [10.1002/jhm.691](https://doi.org/10.1002/jhm.691).
- National Institute for Health and Care Excellence** (2014). Delirium: NICE quality standard 63. UK: National Institute for Health and Care Excellence ([guidance.nice.org.uk/qs63](http://guidance.nice.org.uk/qs63)).
- Nikooie R, Neufeld KJ, Oh ES, Wilson LM, Zhang A, Robinson KA, Needham DM** (2019). Antipsychotics for treating delirium in hospitalized adults: a systematic review. *Annals of Internal Medicine* 171(7), 485–495. doi: [10.7326/M19-1860](https://doi.org/10.7326/M19-1860).
- Rao A, Suliman A, Story G, Vuik S, Aylin P, Darzi A** (2016). Meta-analysis of population-based studies comparing risk of cerebrovascular accident associated with first- and second-generation antipsychotic prescribing in dementia. *International Journal of Methods in Psychiatric Research* 2016;25(4):289–298. doi: [10.1002/mpr.1509](https://doi.org/10.1002/mpr.1509).
- Scottish Intercollegiate Guidelines Network** (2019). Risk reduction and Management of Delirium ([www.sign.ac.uk/sign-157-delirium](http://www.sign.ac.uk/sign-157-delirium)). Accessed April 18th 2020.
- Shah FA, Girard TD, Yende S** (2017). Limiting Sedation for Patients with ARDS—Time to Wake Up. *Current Opinion in Critical Care* 23(1), 45.
- Shenkin SD, Fox C, Godfrey M, Siddiqi N, Goodacre S, et al.** (2019). Delirium detection in older acute medical inpatients: a multicentre prospective comparative diagnostic test accuracy study of the 4AT and the Confusion Assessment Method. *BMC Medicine* 17(1), 138.
- Vozoris NT** (2014) Do benzodiazepines contribute to respiratory problems? *Expert Review of Respiratory Medicine* 8, 661–663. doi: [10.1586/17476348.2014.957186](https://doi.org/10.1586/17476348.2014.957186).
- Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C** (2020). Nervous system involvement after infection with COVID-19 and other coronaviruses [published online ahead of print, 2020 Mar 30]. *Brain, Behavior, and Immunity* doi: [10.1016/j.bbi.2020.03.031](https://doi.org/10.1016/j.bbi.2020.03.031).
- Zhou P, Yang XL, Wang XG, et al.** (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 579, 270–273. doi: [10.1038/s41586-020-2012-7](https://doi.org/10.1038/s41586-020-2012-7).